METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer

BACKGROUND: Chemotherapy is an important strategy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+HER2−) breast cancer (BC), but this subtype has a low response rate to chemotherapy. Growing evidence indicates that N(6)-methyladenosine (m(6)A) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Dengjie, Hong, Tao, Fu, Mengdie, Li, Yitong, Zeng, Liyun, Chen, Qitong, He, Hongye, Wen, Ying, Cheng, Yan, Zhou, Meirong, Zou, Qiongyan, Yi, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921123/
https://www.ncbi.nlm.nih.gov/pubmed/36765397
http://dx.doi.org/10.1186/s13058-022-01598-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921123/
https://www.ncbi.nlm.nih.gov/pubmed/36765397
http://dx.doi.org/10.1186/s13058-022-01598-w

Ejemplares similares